Georges Catinis, MD
Gastroenterology · Metairie, LANPI 1861495285
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (42.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Pfizer at 35.4% of the total. Reporting peaked in 2024 at $232,516 and has fallen 66.4% since, to $78,225 in 2025. Among gastroenterology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 856 payments — averaging $404.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$123K
- Phathom Pharmaceuticals, Inc.$90K
- Lilly USA, LLC$88K
- Eli Lilly$22K
- Regeneron Healthcare Solutions, Inc.$5K
- Gastrogpo, LLC$5K
- plus $14K from 29 others
Across 121 payments — averaging $7681.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$710K
- Bausch Health US, LLC$100K
- Eli Lilly$52K
- AbbVie$42K
- Takeda Pharmaceuticals U.S.A., Inc.$22K
- UCB Biosciences Inc.$4K
What the payments were for
- Consulting fees$146,45142%
- Speaking & faculty fees$147,98843%
- Travel & lodging$32,5699%
- Food & beverage$19,3786%
- Education$570%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 51 | $122,681 |
| Phathom Pharmaceuticals, Inc. | 97 | $90,407 |
| Lilly USA, LLC | 126 | $88,304 |
| Eli Lilly | 11 | $22,150 |
| Regeneron Healthcare Solutions, Inc. | 13 | $4,712 |
| Gastrogpo, LLC | 5 | $4,529 |
| AbbVie(2 entities) | 248 | $4,426 |
| Bausch Health US, LLC | 2 | $2,335 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 80 | $1,107 |
| Gilead | 33 | $968 |
| Johnson & Johnson | 49 | $810 |
| Sanofi | 22 | $786 |
| Bristol Myers Squibb | 28 | $638 |
| Intercept Pharmaceuticals, Inc. | 11 | $431 |
| Ardelyx, Inc. | 13 | $318 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $289 |
| Mindray DS USA, Inc. | 1 | $230 |
| Janssen Scientific Affairs, LLC | 4 | $224 |
| Aimmune Therapeutics, Inc. | 9 | $211 |
| Mallinckrodt Hospital Products Inc. | 1 | $121 |
| Ferring Pharmaceuticals Inc. | 4 | $92 |
| Celltrion USA Inc. | 5 | $91 |
| Ipsen Biopharmaceuticals, Inc | 4 | $77 |
| Teva Pharmaceuticals USA, Inc. | 2 | $67 |
| Romark Laboratories, LC | 2 | $62 |
| E.r. Squibb & Sons, L.L.C. | 1 | $60 |
| Merck | 3 | $55 |
| Novo Nordisk | 3 | $53 |
| Madrigal Pharmaceuticals | 2 | $50 |
| Amgen | 3 | $49 |
| Ironwood Pharmaceuticals, Inc | 2 | $37 |
| Redhill Biopharma Inc. | 1 | $22 |
| Braintree Laboratories, Inc. | 1 | $19 |
| Evoke Pharma, Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$346,443 in reported general payments places this provider in the 95th percentile of 254 gastroenterology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SucraidSacrosidase | 15 | $208,742 |
| RinvoqUpadacitinib | 16 | $103,010 |
| LinzessLinaclotide | 120 | $88,311 |
| Humira(Cf)Adalimumab | 13 | $84,594 |
| CreonLipase/Protease/Amylase | 24 | $82,702 |
| XifaxanRifaximin | 12 | $34,912 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 113 | $18,416 |
| Mesalamine | 61 | $15,686 |
| Entecavir | 18 | $11,148 |
| Famotidine | 491 | $9,470 |
| Sucralfate | 20 | $6,570 |
| SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag | 51 | $6,399 |
| Omeprazole | 324 | $5,754 |
| Pantoprazole Sodium | 620 | $5,731 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 28 | $4,617 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Linzess, Humira(Cf), Creon | $4,426 | $358,618173 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $1,107 | $34,91212 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $92 | $18,416113 claims |
| Braintree Laboratories, Inc.Suflave, Sutab | $19 | $11,01679 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 254 gastroenterology providers in Louisiana.
Other gastroenterology in Metairie
- David SilversMetairie$92K
- Howard BrennerMetairie$19K
- Mark MarinoMetairie$15K
- Nicholas PersichMetairie$15K
- Mark WegmannMetairie$14K
- Vernon CarriereMetairie$13K
- Jonathon ChapmanBaton Rouge$998K
- Conar FittonKenner$955K
- Gia LandryBaton Rouge$511K
- Charles MonierThibodaux$448K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.